DDInter233 DDInter782
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Levonorgestrel
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Brigatinib may lead to a major life threatening interaction when taken with Levonorgestrel
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib